menu
    • menu
    [{"orgOrder":0,"company":"Vivimed Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Vivimed Labs","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Vivimed Labs \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vivimed Labs \/ Not Applicable"},{"orgOrder":0,"company":"Faes Farma","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Faes Farma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Faes Farma \/ Hikma Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Faes Farma \/ Hikma Pharmaceutical"},{"orgOrder":0,"company":"Aralez Pharmaceuticals","sponsor":"Miravo Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Aralez Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aralez Pharmaceuticals \/ Miravo Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Aralez Pharmaceuticals \/ Miravo Healthcare"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bilastine","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Bilastine

    Menu

    Bilastine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tiefenbacher Group

                            Germany
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tiefenbacher Pharmaceuticals Successfully Launches the Antihistamine Bilastine for A Market Entry as Over-the-...

                            Details : Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.

                            Brand Name : Bilastine Tiefenbacher

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 14, 2023

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tiefenbacher Group

                            Germany
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Antihistami...

                            Details : Bilastine is an innovative anti-allergy medicine improving the life of patients suffering from allergic symptoms also a second-generation antihistamine product helps to relieve nasal and non-nasal symptoms of seasonal rhinitis as well as urticaria caused...

                            Brand Name : Bilastine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 20, 2021

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aralez Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed

                            Aralez Pharmaceuticals

                            U.S.A arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Miravo Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Miravo Healthcare™ Announces the Canadian Commercial Launch of Blexten® for Patients 4 Years of Age and Old...

                            Details : Blexten (bilastine) is a second-generation antihistamine drug, exerts its effect through its highly selective inhibition of peripheral histamine H1 receptors for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.

                            Brand Name : Blexten

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2022

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Miravo Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Faes Farma

                            Spain arrow
                            BioFlorida Conference
                            Not Confirmed

                            Faes Farma

                            Spain arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Hikma and FAES Farma Enter Into Exclusive Licensing Agreement for The Commercialisation of Bilastine Tablets I...

                            Details : Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercialisation of the product in the US following approval.

                            Brand Name : Bilaxten

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 20, 2021

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Hikma Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vivimed Labs

                            India arrow
                            BioFlorida Conference
                            Not Confirmed

                            Vivimed Labs

                            India arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vivimed Labs Gets Approval from Uzbekistan Govt for Two Products

                            Details : The company has received approval for Bilastin tablets, which are used for the treatment of allergic Rhino conjunctivitis and Urticaria, the Hyderabad-based company said in a regulatory filing.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 08, 2021

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth